Published in Ann Neurol on May 01, 2007
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet (2010) 5.75
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol (2010) 4.48
Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol (2008) 3.99
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol (2011) 3.63
Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol (2011) 3.34
Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol (2008) 3.13
Probing the biology of Alzheimer's disease in mice. Neuron (2010) 2.96
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96
TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J (2010) 2.90
The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology (2015) 2.81
TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol (2010) 2.81
Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol (2009) 2.76
Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet (2009) 2.50
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48
Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol (2008) 2.44
Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol (2008) 2.41
Neurodegenerative basis of age-related cognitive decline. Neurology (2010) 2.41
TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem (2009) 2.40
A Drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci U S A (2010) 2.36
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol (2010) 2.19
Hippocampal sclerosis in advanced age: clinical and pathological features. Brain (2011) 2.16
Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology (2008) 2.01
Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol (2010) 1.96
Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. J Neurol (2009) 1.85
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75
TDP-43: a novel neurodegenerative proteinopathy. Curr Opin Neurobiol (2007) 1.73
The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. Ann Med (2012) 1.66
TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol (2009) 1.56
Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum Mol Genet (2010) 1.56
Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J Biol Chem (2009) 1.53
Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol (2008) 1.53
Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci (2015) 1.53
Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol (2013) 1.52
ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol (2008) 1.49
Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol (2012) 1.48
TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol (2014) 1.47
TDP-43 in aging and Alzheimer's disease - a review. Int J Clin Exp Pathol (2011) 1.46
Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain (2010) 1.45
TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander. Mamm Genome (2008) 1.44
Neurodegeneration the RNA way. Prog Neurobiol (2011) 1.43
Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol (2013) 1.41
RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion (2011) 1.40
TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol (2013) 1.37
Staging TDP-43 pathology in Alzheimer's disease. Acta Neuropathol (2013) 1.36
Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically. Alzheimer Dis Assoc Disord (2011) 1.35
TDP-43 aggregation in neurodegeneration: are stress granules the key? Brain Res (2012) 1.35
Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol (2013) 1.32
Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain (2015) 1.31
Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly. Neurodegener Dis (2010) 1.31
Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol (2008) 1.31
Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord (2008) 1.29
Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol (2010) 1.29
Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old. Brain (2011) 1.29
TDP-43 immunoreactivity in neurodegenerative disorders: disease versus mechanism specificity. Acta Neuropathol (2007) 1.27
Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol (2009) 1.27
Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch Neurol (2012) 1.26
Molecular neuropathology of TDP-43 proteinopathies. Int J Mol Sci (2009) 1.26
A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol Cell Neurosci (2013) 1.25
The early neuropsychological and behavioral characteristics of frontotemporal dementia. Neuropsychol Rev (2008) 1.25
Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.23
Inflammation in the early stages of neurodegenerative pathology. J Neuroimmunol (2011) 1.21
Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol (2014) 1.21
The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics (2007) 1.20
Progranulin promotes neurite outgrowth and neuronal differentiation by regulating GSK-3β. Protein Cell (2010) 1.19
Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration. Neuropathol Appl Neurobiol (2010) 1.19
TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. Acta Neuropathol (2010) 1.19
TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology (2012) 1.18
Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core. Alzheimers Dement (2010) 1.18
TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest-southwest consortium for FTLD study. J Neuropathol Exp Neurol (2008) 1.16
Caspase-cleaved TAR DNA-binding protein-43 is a major pathological finding in Alzheimer's disease. Brain Res (2008) 1.16
Multiplex SILAC analysis of a cellular TDP-43 proteinopathy model reveals protein inclusions associated with SUMOylation and diverse polyubiquitin chains. Mol Cell Proteomics (2010) 1.16
Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol (2012) 1.14
Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol (2014) 1.13
Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain (2013) 1.13
Elucidating the genetics and pathology of Perry syndrome. J Neurol Sci (2009) 1.12
Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS One (2011) 1.12
The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum Mol Genet (2013) 1.11
Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies. Acta Neuropathol (2008) 1.10
Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer. Acta Neuropathol Commun (2014) 1.09
TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neuropathol (2008) 1.09
Update on recent molecular and genetic advances in frontotemporal lobar degeneration. J Neuropathol Exp Neurol (2008) 1.08
RNA processing pathways in amyotrophic lateral sclerosis. Neurogenetics (2010) 1.08
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol (2014) 1.07
Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol (2010) 1.07
Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease. Acta Neuropathol (2008) 1.06
The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Curr Opin Neurol (2008) 1.05
Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol (2015) 1.03
Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp Gerontol (2012) 1.01
Hippocampal sclerosis of aging is a key Alzheimer's disease mimic: clinical-pathologic correlations and comparisons with both alzheimer's disease and non-tauopathic frontotemporal lobar degeneration. J Alzheimers Dis (2014) 1.00
Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation. PLoS One (2011) 1.00
Lack of TAR-DNA binding protein-43 (TDP-43) pathology in human prion diseases. Neuropathol Appl Neurobiol (2008) 0.99
Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a post-mortem study. Brain (2011) 0.98
Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy. J Neural Transm (Vienna) (2008) 0.98
Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol (2011) 0.97
Neuronal sensitivity to TDP-43 overexpression is dependent on timing of induction. Acta Neuropathol (2012) 0.97
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol (2003) 14.87
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun (2006) 10.69
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol (2006) 4.32
A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A (1990) 4.26
Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol (2006) 4.24
Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (2003) 3.76
Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol (2006) 2.57
Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord (2002) 2.56
Most cases of dementia with hippocampal sclerosis may represent frontotemporal dementia. Neurology (2004) 2.42
Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration. Acta Neuropathol (2004) 2.41
Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. Neurology (1990) 2.36
Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol (2003) 2.20
Frontotemporal dementia. Br J Psychiatry (2002) 1.95
Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol (2002) 1.90
Hippocampal and neocortical ubiquitin-immunoreactive inclusions in amyotrophic lateral sclerosis with dementia. Neurosci Lett (1992) 1.82
cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J Neurosci (1999) 1.63
Dementia of frontal lobe type: neuropathology and immunohistochemistry. J Neurol Neurosurg Psychiatry (1993) 1.62
New ubiquitin-positive intraneuronal inclusions in the extra-motor cortices in patients with amyotrophic lateral sclerosis. Neurosci Lett (1991) 1.60
Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques. Ann Neurol (1997) 1.48
Ubiquitin immunohistochemistry of frontotemporal lobar degeneration differentiates cases with and without motor neuron disease. Alzheimer Dis Assoc Disord (2005) 1.40
Hippocampal sclerosis in tau-negative frontotemporal lobar degeneration. Neurobiol Aging (2006) 1.40
Hippocampal sclerosis dementia with tauopathy. Brain Pathol (2003) 1.34
Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. Am J Pathol (2003) 1.34
Ubiquitin-positive intraneuronal inclusions in the extramotor cortices of presenile dementia patients with motor neuron disease. J Neurol (1992) 1.29
Argyrophilic grain disease: neuropathology, frequency in a dementia brain bank and lack of relationship with apolipoprotein E. Brain Pathol (2002) 1.27
Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clin Neuropathol (1989) 1.26
Different variants of frontotemporal dementia: a neuropathological and immunohistochemical study. Acta Neuropathol (1996) 1.13
Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease. Neurosci Lett (1999) 1.06
Hippocampal sclerosis dementia: expanding the phenotypes of frontotemporal dementias? Neurology (2004) 1.05
Ubiquitin-related cytoskeletal abnormality in frontotemporal dementia: immunohistochemical and immunoelectron microscope studies. Acta Neuropathol (1997) 0.95
Alzheimer disease pathology in amyotrophic lateral sclerosis. Acta Neuropathol (2004) 0.94
Frontal lobe degeneration: novel ubiquitin-immunoreactive neurites within frontotemporal cortex. Neuropathol Appl Neurobiol (1995) 0.88
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron (2013) 5.91
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord (2009) 5.50
Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science (2005) 5.49
Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA (2011) 5.21
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet (2009) 4.00
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 3.79
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. Am J Hum Genet (2006) 3.67
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2009) 3.65
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol (2011) 3.63
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest (2007) 3.35
Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol (2011) 3.34
A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron (2012) 3.32
Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One (2012) 3.11
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain (2012) 3.08
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol (2008) 2.95
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci (2005) 2.94
Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology (2011) 2.90
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76
Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families. Arch Neurol (2007) 2.68
A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A (2011) 2.68
Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med (2011) 2.61
Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci (2010) 2.60
Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA (2013) 2.58
Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol (2006) 2.57
Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord (2002) 2.56
Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol (2003) 2.56
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell (2008) 2.55
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48
Abeta40 inhibits amyloid deposition in vivo. J Neurosci (2007) 2.47
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol (2008) 2.46
Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain (2009) 2.45
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain (2012) 2.43
Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation (2007) 2.43
Detecting dementia with the mini-mental state examination in highly educated individuals. Arch Neurol (2008) 2.42
Risk factors for dementia with Lewy bodies: a case-control study. Neurology (2013) 2.38
Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem (2005) 2.31
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol (2013) 2.29
Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet (2012) 2.23
AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem (2010) 2.21
Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol (2010) 2.20
Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol (2003) 2.20
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol (2007) 2.19